The effect of anti-α4 integrin antibody on brain lesion activity in MS

Neurology

Volumn 53, Issue 3, 1999, Pages 466-472

  Tubridy, N ^a   Behan, P O ^b   Capildeo, R ^c   Chaudhuri, A ^b   Forbes, R ^g   Hawkins, C P ^d   Hughes, R A C ^e   Palace, J ^f   Sharrack, B ^e   Swingler, R ^g   Young, C ^h   Moseley, I F ^a   MacManus, D G ^a   Donoghue, S ⁱ   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c Orsett Hospital   (United Kingdom)

^d UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

^f RADCLIFFE INFIRMARY   (United Kingdom)

^g Dundee Royal Infirmary   (United Kingdom)

^h WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

ⁱ Elan Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN ANTIBODY; BETA1 INTEGRIN; INTEGRIN; NATALIZUMAB; UNCLASSIFIED DRUG; ALPHA4 INTEGRIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; BRAIN; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BRAIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTEGRIN ALPHA4; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 0033546663     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.3.466     Document Type: Article

References (15)

1. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
2. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987;48:549-554.
3. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental allergic encephalomyelitis by antibodies against α4β1 integrin. Nature 1992; 356:63-66.
4. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha-4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10.
5. Kent SJ, Karlik SJ, Rice GPA, Horner HC. A monoclonal antibody to α4-integrin reverses the MRI-detectable signs of experimental allergic encephalomyelitis in the guinea pig. Proc Int Soc Magn Reson Imaging 1994;3:1400. Abstract.
6. Leger JP, Yednock TA, Tanner L, et al. Humanisation of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Human Antibodies 1997;8:3-16.
7. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
9. Sharrack B, Hughes RAC, Soudain S. Guy's Neurological Disability Scale. Neurology 1996;243(suppl 2):S32.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
11. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel groups and cross-over designs. J Neurol Sci 1994;122:6-14.
12. Tubridy N, Ader H, Barkhof F, Thompson AJ, Miller DH. Sample size calculations for MRI outcome pilot trials in multiple sclerosis: relapsing-remitting versus secondary progressive subgroups. J Neurol Neurosurg Psychiatry 1998;64:50-55.
13. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997;120:865-916.
14. Kermode AG, Thompson AJ, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489.
15. Paty DW, Li DKB, UBC MS-RI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multi-centre, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.